Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical scoring methods for multiple sclerosis

J H Noseworthy1

  • 1Department of Neurology, Mayo Clinic, Rochester, MN 55905.

Annals of Neurology
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disability as an outcome in MS clinical trials.

Neurology·2008
Same author

A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis.

Neurology·2005
Same author

Disability profile of MS did not change over 10 years in a population-based prevalence cohort.

Neurology·2004
Same author

Change in MS-related disability in a population-based cohort: a 10-year follow-up study.

Neurology·2004
Same author

Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000.

Neurology·2003
Same author

International consensus statement on the use of disease-modifying agents in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2002
Same journal

Reply to "Clinical Value of Aneurysm Wall Enhancement in Unruptured Intracranial Aneurysm".

Annals of neurology·2026
Same journal

Clinical Value of Aneurysm Wall Enhancement in Unruptured Intracranial Aneurysm.

Annals of neurology·2026
Same journal

Imaging of Neurovascular Compression in Thoracic Outlet Syndrome.

Annals of neurology·2026
Same journal

Reply to "Methodological Challenges in Interpreting SAA-Defined Imaging Subgroups in Parkinson's Disease".

Annals of neurology·2026
Same journal

Methodological Challenges in Interpreting SAA-Defined Imaging Subgroups in Parkinson's Disease.

Annals of neurology·2026
Same journal

The Financial Value of an Academic Neurologist.

Annals of neurology·2026
See all related articles

Multiple Sclerosis (MS) clinical rating scales like the EDSS are familiar but have limitations. Magnetic Resonance Imaging (MRI) shows greater sensitivity in detecting MS disease activity than clinical assessments.

Area of Science:

  • Neurology
  • Clinical Trials
  • Biomarkers

Background:

  • Clinical rating scales are essential for assessing neurological dysfunction and treatment response in Multiple Sclerosis (MS).
  • The Expanded Disability Status Scale (EDSS) is widely used but has limitations in consistency and sensitivity, particularly in mid-to-higher disability ranges.
  • Objective, reliable, and sensitive measures are needed to accurately track MS disease activity.

Purpose of the Study:

  • To evaluate the utility of existing clinical rating scales in Multiple Sclerosis (MS).
  • To highlight the limitations of current clinical assessments, such as the EDSS.
  • To emphasize the need for more objective measures, including advanced imaging techniques.

Main Methods:

  • Review of existing literature on Multiple Sclerosis (MS) clinical rating scales.

Related Experiment Videos

  • Comparison of the sensitivity of clinical methods versus Magnetic Resonance Imaging (MRI) in detecting MS disease activity.
  • Discussion of the challenges in clinical trial outcome measures.

    • Main Results:

    • The Expanded Disability Status Scale (EDSS) is familiar but suffers from inter-evaluator variability and insensitivity to certain clinical changes.
    • Magnetic Resonance Imaging (MRI) studies are significantly more sensitive (7- to 10-fold) than clinical methods in detecting subclinical MS disease activity.
    • Evaluator unblinding can compromise the validity of clinical assessments in treatment response.

    Conclusions:

    • Current clinical rating scales for Multiple Sclerosis (MS), including the EDSS, require improvement in objectivity and sensitivity.
    • Serial Magnetic Resonance Imaging (MRI) shows promise as a more sensitive tool for monitoring MS disease activity.
    • Further research is needed to validate MRI findings as reliable predictors of irreversible pathology and future disability in MS.